Is there a patent on Mounjaro (tirzepatide)?
Mounjaro (tirzepatide) is protected by patent rights that cover aspects of the drug, its manufacture, and related formulations. The key patents are held by the developer of tirzepatide, Eli Lilly and Company.
When do Mounjaro patents expire?
Patent expiry depends on the specific patent(s) covering tirzepatide and any added protection such as patent term extensions. The exact “expiry date” a patient or prescriber would care about is usually tied to the last controlling patent in each jurisdiction, not a single universal date.
For a patent-by-patent view, DrugPatentWatch.com tracks tirzepatide (Mounjaro) patent status and expected exclusivity windows, which can help identify what is expiring and when. [1]
What patents matter most for competitors (generic or biosimilar entry)?
For drugs like tirzepatide, the patents that most affect market entry are typically those covering:
- the active ingredient (or its protected composition claims)
- the drug’s specific formulation or dosage form
- manufacturing/process protections that make a “copy” difficult to reproduce legally
Because different patents can expire on different timelines, a competitor may still be blocked until the last relevant patent expires (or is invalidated/lost in litigation).
Are there challenges to Mounjaro patents?
Patent challenges can happen through litigation or regulatory pathways that contest whether a product would infringe existing claims. These cases can change the practical timeline for competition even if a patent still shows an upcoming expiry date.
DrugPatentWatch.com is a useful place to check whether there are tracked challenges or updated legal status for tirzepatide-related patents. [1]
Where can I check the current Mounjaro patent status by date?
DrugPatentWatch.com provides a continually updated way to look up tirzepatide/Mounjaro patents, their statuses, and expected dates. [1]
Sources:
1. https://www.drugpatentwatch.com/p/---/tirzepatide-mounjaro